Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials

Find Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials Near You

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Who is this study for? Pediatric patients age 8 to 12 years with attention deficit hyperactivity disorder
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The study team will examine the effects of FDA approved stimulant and non-stimulant medications for ADHD, among youth with ADHD and with and without Oppositional Defiant Disorder (ODD) or Conduct Disorder (CD), on reward systems of the brain using fMRI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 7
Maximum Age: 12
Healthy Volunteers: f
View:

• Pre-pubertal (e.g. Tanner stage 1 or 2)

• Age 7-12 inclusive

• Signed consent/assent

• Parent communicates sufficiently in English to provide informed consent and complete assessment instruments;

• ADHD as determined by computerized DISC (C-DISC) parent interview

• ADHD-Rating Scale-5 total score (interview with parent )

• SNAP ADHD total score (teacher) of 1.5 SD \> age/sex norms

• CD or severe ODD: CD or ODD + 2 symptoms of CD on C-DISC

• SNAP ODD/CD subscale (parent and teacher) 1.5 SD \> age/sex norms

Locations
United States
New York
Icahn School of Medicine at Mount Sinai
RECRUITING
New York
Contact Information
Primary
Beth Krone, PhD
beth.krone@mssm.edu
212-241-8012
Backup
Jeffrey Newcorn, MD
Time Frame
Start Date: 2019-06-04
Estimated Completion Date: 2025-09-25
Participants
Target number of participants: 44
Treatments
Active_comparator: Methylphenidate
0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
Active_comparator: Atomoxetine
0.5 mg/kg for 1 week and 1 mg/kg for 2 weeks
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: Icahn School of Medicine at Mount Sinai

This content was sourced from clinicaltrials.gov

Similar Clinical Trials